標(biāo)題: Titlebook: Angiotensin II Receptor Blockade Physiological and Clinical Implications; Naranjan S. Dhalla (Distinguished Professor and Di Book 1998 Spr [打印本頁] 作者: 貪求 時(shí)間: 2025-3-21 16:05
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications影響因子(影響力)
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications影響因子(影響力)學(xué)科排名
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications網(wǎng)絡(luò)公開度
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications被引頻次
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications被引頻次學(xué)科排名
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications年度引用
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications年度引用學(xué)科排名
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications讀者反饋
書目名稱Angiotensin II Receptor Blockade Physiological and Clinical Implications讀者反饋學(xué)科排名
作者: Ointment 時(shí)間: 2025-3-21 23:48 作者: meretricious 時(shí)間: 2025-3-22 01:13
Cellular Physiology of Angiotensin II Receptors in Vascular Smooth Muscle Cellsnctions have been defined. The developmental regulation of AT. receptor expression, however, suggests that it may be important in ontogeny. Furthermore, the generation of an AT. receptor knockout mouse has revealed that this receptor, although its absence is not lethal, governs both the drinking res作者: 凹室 時(shí)間: 2025-3-22 06:22
Angiotensin II Enhanced The Expression Of Inhibitory Guanine Nucleotide Regulatory Protein in Vasculrotein as well as the attenuated responsiveness of adenylyl cyclase to Ang II and C-ANP. inhibition. The results suggest the implication of AT. receptor in Ang II-induced increases of Giα protein expression in vascular smooth muscle cells.作者: 多產(chǎn)魚 時(shí)間: 2025-3-22 08:57
Comparison of the Inhibitory Actions of Angiotensin AT1 Receptor Antagonists in the Peripheral Vascurictor responses to the angiotensin peptides in the regional vascular bed of the cat. In the rat, candesartan decreased pressor responses to Ang II, whereas PD 123,319 had no effect on the response to the peptide. These results indicate that vasoconstrictor responses to Ang peptides in the regional 作者: itinerary 時(shí)間: 2025-3-22 14:33 作者: TATE 時(shí)間: 2025-3-22 19:41 作者: epinephrine 時(shí)間: 2025-3-22 21:58
Exploring the Difference Between Angiotensin Converting Enzyme Inhibitors and Angiotensin II-Recepto that would compare agents with a bradykinin effect, namely, ACE inhibitors, with those without a bradykinin effect. Thus far, the trials have shown great similarity between the agents in the field of hypertension and those of cardiac failure.作者: Cholagogue 時(shí)間: 2025-3-23 03:44 作者: 蘑菇 時(shí)間: 2025-3-23 07:15
In Pursuit of Optimal Care and Outcomes for Patients with Congestive Heart Failure: Insights from thprogression of heart failure, although noncardiac causes, particularly cancer and pulmonary diseases, account for about 30 percent of all deaths. Therapy proven to reduce overall mortality in CHF is presently limited to angiotensin-converting enzyme inhibitors (ACEI) , although angiotensin receptor 作者: 平靜生活 時(shí)間: 2025-3-23 12:32
Sarah L. Beringer,Sylvia Maier,Markus Thielen expressed that the alternatives to ACE inhibition may lack some therapeutic features, it is suspected that blockade at the renin or the Ang II receptor levels will block the system more effectively, and thus may provide a positive alternative. The renin inhibitor is more effective because the int作者: faction 時(shí)間: 2025-3-23 14:52 作者: asthma 時(shí)間: 2025-3-23 21:06 作者: Compass 時(shí)間: 2025-3-23 23:26 作者: 違抗 時(shí)間: 2025-3-24 03:24 作者: inculpate 時(shí)間: 2025-3-24 09:01
EU Digital Copyright Law and the End-Userted in a series of publications in the Canadian Medical Association Journal in 1993. Specific reviews dealt with the pharmacotherapy of hypertension, the treatment of hypertension in the elderly, and the treatment of the diabetic hypertensive. The choice of antihypertensive therapy is driven by fact作者: jabber 時(shí)間: 2025-3-24 11:17
EU Digital Copyright Law and the End-Userthough mechanisms of their respective transcriptional control seemed to be different. By computer-assisted modeling and site-directed mutagenesis, we have delineated the docking site of Ang II. AT. (and AT.) serves most of the commonly recognized actions of Ang II. In addition, this G protein-couple作者: Anthrp 時(shí)間: 2025-3-24 15:37 作者: tangle 時(shí)間: 2025-3-24 22:34 作者: 宇宙你 時(shí)間: 2025-3-25 01:44 作者: obligation 時(shí)間: 2025-3-25 05:27 作者: 草率男 時(shí)間: 2025-3-25 09:49 作者: 誓言 時(shí)間: 2025-3-25 14:03 作者: 口音在加重 時(shí)間: 2025-3-25 19:02
Book 1998ndicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor b作者: Scintillations 時(shí)間: 2025-3-25 20:42 作者: 小蟲 時(shí)間: 2025-3-26 01:45
The Brain Renin-Angiotensin System And Salt-Sensitive Hypertensions, peptides, and receptors of the brain RAS and the organization of angiotensinergic pathways involved in cardiovascular regulation. Centrally administered exogenous angiotensin (Ang) II increases sympathetic neuronal activity, decreases the gain of the baroreflex, and induces vasopressin release. A作者: 描述 時(shí)間: 2025-3-26 06:56
At1 Angiotensin Receptor Blockade and Angiotensin Converting Enzyme Inhibition: Effects on Vascular istar-Kyoto control rats (WKY). These differences may be reduced by treatment with angiotensin I-converting enzyme inhibitors (ACEI). It is unclear whether this beneficial effect is the result of inhibition of the generation of angiotensin (Ang) II by ACEI or the result of increased bradykinin accum作者: Missile 時(shí)間: 2025-3-26 11:25
Cellular Physiology of Angiotensin II Receptors in Vascular Smooth Muscle Cells. Regardless of its origin, the response of cardiovascular tissues to Ang II is mediated by specific cell surface receptors. In vascular tissues, two angiotensin receptors have been characterized according to their sensitivity to the specific antagonists losartan and PD123319 [1]. The AT. receptor (作者: exceed 時(shí)間: 2025-3-26 12:47
Angiotensin II Enhanced The Expression Of Inhibitory Guanine Nucleotide Regulatory Protein in Vasculnctions in A-10 vascular smooth muscle cells (VSMCs). Ang II treatment of VSMC enhanced the levels of inhibitory guanine nucleotide regulatory protein (Gi) as well as Gi mRNA in a concentration-dependent manner as determined by immunoblot and Northern blot analysis, respectively. However, the GTPγS-作者: 詞匯 時(shí)間: 2025-3-26 20:26 作者: 不利 時(shí)間: 2025-3-26 22:30 作者: Substance-Abuse 時(shí)間: 2025-3-27 04:03
The Place of Angiotensin II Antagonists in Relation to the Canadian Hypertension Society Guidelineso be effective than the earlier pharmacological approach of inhibiting the enzyme (ACE inhibitor) responsible for converting Ang I to Ang II. Furthermore, it is expected that the approach will avoid problems associated with pathways that bypass ACE, e.g., tissue chymase..Two major subtypes of recept作者: 思考 時(shí)間: 2025-3-27 06:17 作者: Picks-Disease 時(shí)間: 2025-3-27 11:27
Cough Induced by Pharmacological ModulatiOn of the Renin-Angiotensin-Aldosterone System. Angiotensing a different class of antihypertensive agents for the offending ACE inhibitors. Losartan potassium represents a new class of antihypertensive agents with a different mechanism of action: it directly blocks the effects of angiotensin (Ang) II at the receptor level, without affecting kininase II-rela作者: ADORE 時(shí)間: 2025-3-27 17:11 作者: 橢圓 時(shí)間: 2025-3-27 19:50
Angiotensin Receptor Antagonists and Cardiovascular Remodeling in the vascular and cardiac remodeling observed in response to chronic or acute hypertension. Two major Ang II receptor subtypes, AT. and AT., have been described, and their roles in vivo and in vitro have now been investigated using nonpeptidic antagonists, losartan and PD123319, which block AT. a作者: COM 時(shí)間: 2025-3-27 23:56 作者: Pageant 時(shí)間: 2025-3-28 04:52
Functional Analysis of Tissue Renin-Angiotensin System Using “Gain and Loss of Function” Approaches:vo studies are limited. Recent progress in in vivo gene transfer technologies have provided us with the opportunity to study cellular responses to the manipulation of the individual components (i.e., by overexpression or inhibition). Currently, many researchers have developed many in vivo gene trans作者: 失望未來 時(shí)間: 2025-3-28 08:50 作者: Tempor 時(shí)間: 2025-3-28 12:49
Role of Cytokines in Septic Cardiomyopathyf human septic myocardial depression in intensive care patients was only unequivocally proved in the 1980s by the group of Parrillo, utilizing a nuclear imaging technique. Septic cardiomyopathy is frequently masked by a seemingly normal cardiac output. However, relative to the lowered systemic vascu作者: 門閂 時(shí)間: 2025-3-28 17:34 作者: 公社 時(shí)間: 2025-3-28 19:23
Sarah L. Beringer,Sylvia Maier,Markus Thielprocesses and in the pathogenesis of disease. Blocking the system pharmacologically is a crucial line of investigation, a function ordinarily played by glandular ablation and hormone replacement. The pharmacological agents, on the other hand, are often plagued by actions which contribute to ambiguit作者: Entrancing 時(shí)間: 2025-3-28 23:28 作者: CLOT 時(shí)間: 2025-3-29 04:51 作者: anachronistic 時(shí)間: 2025-3-29 09:43
https://doi.org/10.1007/978-3-540-76985-0. Regardless of its origin, the response of cardiovascular tissues to Ang II is mediated by specific cell surface receptors. In vascular tissues, two angiotensin receptors have been characterized according to their sensitivity to the specific antagonists losartan and PD123319 [1]. The AT. receptor (作者: Malcontent 時(shí)間: 2025-3-29 15:24 作者: Hot-Flash 時(shí)間: 2025-3-29 17:20
https://doi.org/10.1007/978-3-540-76985-0nd the rat. Under constant flow conditions, injections of angiotensin (Ang) I, Ang II, Ang III, Ang I-(3-10), (Pro.,D-Ala.) Ang I and Ang IV into the hindlimb perfusion circuit caused dose-dependent increases in perfusion pressure, while Ang I-(4-8) was without effect. The order of potency was Ang I作者: 逢迎白雪 時(shí)間: 2025-3-29 21:00 作者: 符合國(guó)情 時(shí)間: 2025-3-30 00:08 作者: Bureaucracy 時(shí)間: 2025-3-30 04:47
EU Digital Copyright Law and the End-Usert care. Considering the complexity of some guidelines, the time constraints of clinical practice, and the discrepancies between patients’ characteristics and entry criteria for clinical trials, one can wonder whether practice guidelines and practicing medicine are compatible [1]. In the past, most o作者: Gyrate 時(shí)間: 2025-3-30 09:10 作者: Presbyopia 時(shí)間: 2025-3-30 15:30 作者: outskirts 時(shí)間: 2025-3-30 18:47
EU Digital Copyright Law and the End-User in the vascular and cardiac remodeling observed in response to chronic or acute hypertension. Two major Ang II receptor subtypes, AT. and AT., have been described, and their roles in vivo and in vitro have now been investigated using nonpeptidic antagonists, losartan and PD123319, which block AT. a作者: 排斥 時(shí)間: 2025-3-30 21:46
EU Digital Copyright Law and the End-Userve heart failure. The development of losartan, a biphenyltetrazole derivative, was based on a carefully managed, rational drug design aimed at improving the low-oral bioavailability normally observed with peptide antagonists. The drug was also designed to preserve selectivity at the AT. receptor sit作者: 畢業(yè)典禮 時(shí)間: 2025-3-31 01:36 作者: 愚蠢人 時(shí)間: 2025-3-31 08:36
EU Digital Copyright Law and the End-Userssault was further amplified by the introduction, in Canada, of the first angiotensin receptor antagonist, an agent that appeared to be devoid of activities involving bradykinin. Intriguingly, this assault was also fueled by some pharmaceutical companies who had ACE inhibitors, but no angiotensin re作者: 驚奇 時(shí)間: 2025-3-31 11:35 作者: OMIT 時(shí)間: 2025-3-31 15:36 作者: 行為 時(shí)間: 2025-3-31 21:01
Angiotensin II Receptor Blockade Physiological and Clinical Implications978-1-4615-5743-2Series ISSN 1389-1774 作者: 懸崖 時(shí)間: 2025-4-1 01:03
https://doi.org/10.1007/978-1-4615-5743-2Angiotensin II; blood pressure; cardiovascular; heart; hypertension作者: 全能 時(shí)間: 2025-4-1 05:07
978-1-4613-7631-6Springer Science+Business Media New York 1998
